Related Experiment Video
Updated: Jul 4, 2026

Introduction of Intracapsular Rotary-cut Procedures (IRCP): A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
Is expensive always better? Comparison of two induction agents for term rupture of membranes
1Department of Obstetrics and Gynaecology, North Middlesex University Hospital, London, UK.mparisaei@hotmail.com
Abstract:
The aim of this study was to compare the clinical safety and efficacy of sublingual misoprostol with vaginal prostaglandin E2 (Prostin(R)) as an induction agent after term rupture of membranes. This was a non-blinded randomised control study involving 57 women who were >24-48 h after term rupture of membranes. In total, 29 women received sublingual misoprostol and 28 received Prostin. The mean induction of labour to delivery time was 20.71+/-11.59 h in the Prostin group and 13.96+/-9.90 h in the misoprostol group, (p = 0.021). Some 46.4 % (13/28) of the Prostin group needed a second dose compared with only 20.7 % (6/29) of the misoprostol group (p = 0.039). Oxytocin infusion was used by 57% (16/28) of the Prostin group compared with 31% (9/29) of those who had received misoprostol, (p = 0.047). In our study, sublingual misoprostol when compared with vaginal prostaglandin E2 gel (Prostin) leads to a shorter induction to labour time, and less need for second dose of induction agent or oxytocin infusion. Women were given a satisfaction questionnaire to complete after delivery. Those who were given misoprostol were satisfied with the outcome, would use it again in the future, and recommend it to friends in similar circumstances.
Related Concept Videos
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Parenteral Anesthetics: Overview
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence